1. Saint-Raymond A, de Vries CS. Medicine safety in pregnancy and ambitions for the EU medicine regulatory framework. Clin Pharmacol Ther. 2016;100(1):21–3. doi:
10.1002/cpt.378
.
2. Gelperin K, Hammad H, Leishear K, Bird ST, Taylor L, Hampp C, et al. A systematic review of pregnancy exposure registries: examination of protocol-specified pregnancy outcomes, target sample size, and comparator selection. Pharmacoepidemiol Drug Saf. 2016;. doi:
10.1002/pds.4150
.
3. INC Research. International Lemtrada pregnancy exposure cohort in multiple sclerosis: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Document No.: OBS13436; 2014.
http://www.encepp.eu/encepp/viewResource.htm?id=7575
. Accessed 8 Dec 2015.
4. Biogen. Tecfidera (dimethyl fumarate) pregnancy exposure registry: European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Document No.: TECGISTRY; 2015.
http://www.encepp.eu/encepp/viewResource.htm?id=8379
. Accessed 8 Dec 2015.
5. Li J, Fox RJ, Phillips JT, Havrdova E, Bar-Or A, Kappos L, et al., editors. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. In: 31st Congress on the European Committee for Treatment and Research in Multiple Sclerosis, Barcelona; 2015.